Author

J. J. Orme

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Y. Yan· 2 shared A. Feven· 1 shared A. S. Mansfield· 1 shared D. Owen· 1 shared D. Wang· 1 shared D. Wu· 1 shared E. R. Dellacecca· 1 shared F. Lucien· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Y. Yan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Resilient CD8+ T cells maintain a high cytotoxic capacity by balancing ROS via ME1 upregulation

J. K. Gicobi, Z. Mao, G. DeFranco, Y. Li, X. Liu, J. B. Hirdler, V. V. Vianzon, E. R. Dellacecca, M. A. Hsu, W. Barham, Y. H. Kim, A. Feven, W. S. Harmsen, Y. Yan, R. S. Dronca, , H. Dong

This paper identifies CX3CR1+ CD8+ T cells with low mitochondrial membrane potential as functionally resilient, showing high cytotoxicity and reduced ROS through ME1 upregulation, which enhances their anti-tumor activity.

bioRxiv · Nov 25, 2022 · PreprintImmunology

A targetable epigenetic vulnerability in PI3K/AKT inhibitor resistant cancers

H. Huang, D. Wu, Y. Yan, T. Wei, Z. Ye, Y. Xiao, Y. Pan, J. J. Orme, D. Wang, L. Wang, S. Ren

This study identifies an epigenetic vulnerability in PI3K/AKT inhibitor-resistant cancers, showing that targeting bromodomain or HDAC inhibitors can overcome resistance by modulating histone acetylation at growth factor/receptor gene loci.

bioRxiv · Aug 27, 2020 · PreprintCancer Biology